Holen Sie sich die Stockscreener-App
6.19
4.00%
0.22
Schlusskurs vom Vortag:
$5.97
Offen:
$5.84
24-Stunden-Volumen:
49,812
Relative Volume:
0.85
Marktkapitalisierung:
$137.93M
Einnahmen:
$56.13M
Nettoeinkommen (Verlust:
$-14.67M
KGV:
-8.3649
EPS:
-0.74
Netto-Cashflow:
$-9.13M
1W Leistung:
+1.12%
1M Leistung:
+10.28%
6M Leistung:
-0.97%
1J Leistung:
+82.62%
1-Tages-Spanne:
$5.64
$6.27
1-Wochen-Bereich:
$5.51
$6.27
52-Wochen-Spanne:
$3.2001
$6.8899
Journey Medical Corp Stock (DERM) Company Profile
Firmenname
Journey Medical Corp
Sektor
Telefon
480-434-6670
Adresse
9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE
Vergleichen Sie DERM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DERM
Journey Medical Corp
|
6.21 | 137.93M | 56.13M | -14.67M | -9.13M | -0.74 |
|
ZTS
Zoetis Inc
|
163.50 | 72.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 47.08B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.15 | 45.99B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.32 | 17.38B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.87 | 14.05B | 612.78M | -86.37M | -62.91M | -0.87 |
Journey Medical Corp Stock (DERM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | ROTH MKM | Buy |
| 2021-12-07 | Eingeleitet | B. Riley Securities | Buy |
Journey Medical Corp Aktie (DERM) Neueste Nachrichten
Q1 EPS Estimates for Journey Medical Reduced by Roth Capital - MarketBeat
Journey Medical appoints new COO amid growth phase - Investing.com
Journey Medical Strengthens Leadership: New COO to Drive Emrosi Launch Strategy - Stock Titan
Journey Medical (NASDAQ:DERM) Issues Earnings Results - MarketBeat
Q3 EPS Estimates for Journey Medical Boosted by Roth Capital - MarketBeat
FY2027 EPS Estimate for Journey Medical Decreased by Analyst - Defense World
FY2027 EPS Estimates for Journey Medical Reduced by Analyst - MarketBeat
Roth Capital Lowers Earnings Estimates for Journey Medical - Defense World
Q3 EPS Estimates for Journey Medical Increased by Analyst - Defense World
Journey Medical Corporation (NASDAQ:DERM) Q4 2024 Earnings Call Transcript - Insider Monkey
Journey Medical Reports 2024 Financial Results - TipRanks
Journey Medical’s Earnings Call Highlights MROSI Launch and Growth Potential - TipRanks
Journey Medical Corp (DERM) Q4 2024 Earnings Call Highlights: Strategic Launch of Emrosi and ... By GuruFocus - Investing.com Canada
Journey Medical earnings beat by $0.27, revenue fell short of estimates - Investing.com
Earnings call transcript: Journey Medical Q4 2024 reveals revenue miss By Investing.com - Investing.com South Africa
Earnings call transcript: Journey Medical Q4 2024 reveals revenue miss - Investing.com India
Earnings call transcript: Journey Medical’s Q4 2024 results highlight IMROCI launch - Investing.com
Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates - Yahoo Finance
Journey Medical reports FY24 EPS (72c) vs (21c) last year - TipRanks
Journey Medical Corp reports results for the quarter ended December 31Earnings Summary - TradingView
FDA Green Light for Journey Medical's Rosacea Drug Reshapes 2024 Performance - Stock Titan
Earnings Scheduled For March 26, 2025 - Benzinga
New Study Compares Topical Serum and Pulse Light Therapy for Rosacea - Dermatology Times
Journey Medical launches Emrosi for the treatment of rosacea - Yahoo Finance
Power Up the Teyvat Journey: UGREEN Launches Genshin Impact Co-Branded Charging Collection - Yahoo Finance
23andMe's journey from DNA testing pioneer to bankruptcy - Yahoo Finance
Journey Medical Launches Emrosi, a Dual-Release Minocycline for Rosacea - Dermatology Times
Breakthrough: First Low-Dose Minocycline Treatment for Rosacea Shows Superior Results - Stock Titan
Short Interest in Journey Medical Co. (NASDAQ:DERM) Grows By 20.5% - MarketBeat
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 - Yahoo Finance
Journey Medical Sets Date for 2024 Annual Results: Dermatology Leader's Financial Update - Stock Titan
Journey Medical (DERM) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Claude Maraoui Sells 49,271 Shares of Journey Medical Co. (NASDAQ:DERM) Stock - MarketBeat
Journey Medical Co. (NASDAQ:DERM) CEO Sells $74,674.05 in Stock - MarketBeat
Journey Medical (DERM) to Release Quarterly Earnings on Thursday - Defense World
Stocks Rally as US Consumer Prices Cool - The Globe and Mail
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference - The Manila Times
Journey Medical CEO Sets Stage for Major Updates at ROTH Conference - StockTitan
Journey Medical’s CEO sells $246,847 in stock By Investing.com - Investing.com South Africa
CEO Cashes Out: Major Stock Sale at Journey Medical Corp - TipRanks
Journey Medical’s CEO sells $246,847 in stock - Investing.com India
Journey Medical CEO Claude Maraoui sells shares worth $203,451 By Investing.com - Investing.com Canada
Journey Medical CEO Claude Maraoui sells shares worth $203,451 - Investing.com Australia
Journey Medical Co. (NASDAQ:DERM) CEO Sells $122,006.52 in Stock - MarketBeat
Claude Maraoui Sells 18,147 Shares of Journey Medical Co. (NASDAQ:DERM) Stock - MarketBeat
Dario Expands Behavioral Health Offerings to Include a Provider Network Through Strategic Arrangement with Rula - PR Newswire
Journey Medical CEO Claude Maraoui sells $360,761 in shares By Investing.com - Investing.com UK
Finanzdaten der Journey Medical Corp-Aktie (DERM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Journey Medical Corp-Aktie (DERM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Maraoui Claude | President & CEO |
Mar 06 '25 |
Sale |
5.04 |
25,551 |
128,777 |
2,067,323 |
| Maraoui Claude | President & CEO |
Mar 07 '25 |
Sale |
5.01 |
14,905 |
74,674 |
2,052,418 |
| Maraoui Claude | President & CEO |
Mar 04 '25 |
Sale |
5.04 |
28,901 |
145,661 |
2,111,021 |
| Maraoui Claude | President & CEO |
Mar 03 '25 |
Sale |
5.19 |
23,508 |
122,007 |
2,139,922 |
| Maraoui Claude | President & CEO |
Mar 05 '25 |
Sale |
5.13 |
18,147 |
93,094 |
2,092,874 |
| Benesch Joseph | CFO |
Feb 21 '25 |
Sale |
5.19 |
1,365 |
7,084 |
45,966 |
| Benesch Joseph | CFO |
Aug 01 '24 |
Sale |
5.47 |
9,324 |
51,002 |
47,331 |
| Benesch Joseph | CFO |
Jul 23 '24 |
Sale |
5.40 |
4,055 |
21,897 |
56,655 |
0.09%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):